AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $160,865 | -89.4% | 13,229 | -89.3% | 0.00% | -75.0% |
| Q4 2022 | $1,514,663 | +37.3% | 124,051 | +17.4% | 0.00% | +100.0% |
| Q3 2022 | $1,103,000 | -17.8% | 105,688 | -15.4% | 0.00% | 0.0% |
| Q2 2022 | $1,342,000 | -17.7% | 124,910 | -27.5% | 0.00% | 0.0% |
| Q1 2022 | $1,631,000 | -0.5% | 172,235 | +21.3% | 0.00% | +100.0% |
| Q4 2021 | $1,640,000 | +23.2% | 141,968 | +1.8% | 0.00% | 0.0% |
| Q3 2021 | $1,331,000 | -9.0% | 139,412 | -8.2% | 0.00% | -50.0% |
| Q2 2021 | $1,463,000 | -48.7% | 151,806 | -47.4% | 0.00% | -50.0% |
| Q1 2021 | $2,854,000 | +38.9% | 288,842 | +224.7% | 0.00% | 0.0% |
| Q4 2020 | $2,054,000 | +48.6% | 88,966 | -9.1% | 0.00% | 0.0% |
| Q3 2020 | $1,382,000 | +68.1% | 97,853 | +9.9% | 0.00% | -42.9% |
| Q1 2020 | $822,000 | +180.5% | 88,999 | +195.9% | 0.01% | +250.0% |
| Q4 2019 | $293,000 | +365.1% | 30,080 | +280.2% | 0.00% | +100.0% |
| Q3 2019 | $63,000 | -25.9% | 7,912 | +16.0% | 0.00% | 0.0% |
| Q2 2019 | $85,000 | -84.2% | 6,823 | -87.8% | 0.00% | -80.0% |
| Q4 2018 | $538,000 | +532.9% | 56,152 | +701.4% | 0.01% | +400.0% |
| Q3 2018 | $85,000 | -91.7% | 7,007 | -89.3% | 0.00% | -88.9% |
| Q2 2018 | $1,026,000 | -48.7% | 65,684 | -50.6% | 0.01% | -55.0% |
| Q1 2018 | $1,999,000 | -8.1% | 132,917 | -12.1% | 0.02% | +33.3% |
| Q4 2017 | $2,176,000 | -48.7% | 151,195 | -46.3% | 0.02% | -61.5% |
| Q3 2017 | $4,242,000 | +139.0% | 281,330 | -21.2% | 0.04% | +129.4% |
| Q4 2016 | $1,775,000 | -54.8% | 357,131 | -11.8% | 0.02% | -63.0% |
| Q4 2015 | $3,926,000 | +100.6% | 404,791 | +189.3% | 0.05% | +70.4% |
| Q3 2015 | $1,957,000 | -0.2% | 139,913 | -40.7% | 0.03% | -10.0% |
| Q4 2014 | $1,961,000 | +94.9% | 235,756 | +39.4% | 0.03% | +100.0% |
| Q3 2014 | $1,006,000 | +232.0% | 169,135 | +86.7% | 0.02% | +200.0% |
| Q2 2014 | $303,000 | +818.2% | 90,589 | +472.1% | 0.01% | +400.0% |
| Q1 2014 | $33,000 | -13.2% | 15,835 | -3.2% | 0.00% | 0.0% |
| Q4 2013 | $38,000 | +35.7% | 16,363 | +36.9% | 0.00% | 0.0% |
| Q3 2013 | $28,000 | -84.2% | 11,950 | -84.3% | 0.00% | -75.0% |
| Q2 2013 | $177,000 | – | 76,143 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |